Abstract
In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kδ) and gamma (PI3Kγ) as therapeutic targets for the treatment of inflammatory and autoimmune diseases. All class 1 PI3-kinases (α/β/γ/δ) generate phospholipid second messengers that help govern cellular processes such as migration, proliferation, and apoptosis. PI3K δ/γ lipid kinases are mainly restricted to the hematopoetic system whereas PI3Kα/β are ubiquitously expressed, thus raising potential toxicity concerns for chronic indications such as asthma and rheumatoid arthritis. Therefore, the challenge in developing a small molecule inhibitor of PI3K is to define and attain the appropriate isoform selectivity profile. Significant advances in the design of such compounds have been achieved by utilizing x-ray crystal structures of various inhibitors bound to PI3Kγ in conjunction with pharmacophore modeling and high-throughput screening. Herein, we review the history and challenges involved with the discovery of small molecule isoform-specific PI3K inhibitors. Recent progress in the design of selective PI3Kδ, PI3Kγ, and PI3Kδ/γ dual inhibitors will be presented.
Keywords: PI3K, inflammation, allergy, asthma, rheumatoid arthritis, COPD
Current Topics in Medicinal Chemistry
Title: Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Volume: 9 Issue: 8
Author(s): Michael K. Ameriks and Jennifer D. Venable
Affiliation:
Keywords: PI3K, inflammation, allergy, asthma, rheumatoid arthritis, COPD
Abstract: In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kδ) and gamma (PI3Kγ) as therapeutic targets for the treatment of inflammatory and autoimmune diseases. All class 1 PI3-kinases (α/β/γ/δ) generate phospholipid second messengers that help govern cellular processes such as migration, proliferation, and apoptosis. PI3K δ/γ lipid kinases are mainly restricted to the hematopoetic system whereas PI3Kα/β are ubiquitously expressed, thus raising potential toxicity concerns for chronic indications such as asthma and rheumatoid arthritis. Therefore, the challenge in developing a small molecule inhibitor of PI3K is to define and attain the appropriate isoform selectivity profile. Significant advances in the design of such compounds have been achieved by utilizing x-ray crystal structures of various inhibitors bound to PI3Kγ in conjunction with pharmacophore modeling and high-throughput screening. Herein, we review the history and challenges involved with the discovery of small molecule isoform-specific PI3K inhibitors. Recent progress in the design of selective PI3Kδ, PI3Kγ, and PI3Kδ/γ dual inhibitors will be presented.
Export Options
About this article
Cite this article as:
Ameriks K. Michael and Venable D. Jennifer, Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ, Current Topics in Medicinal Chemistry 2009; 9 (8) . https://dx.doi.org/10.2174/156802609789044434
DOI https://dx.doi.org/10.2174/156802609789044434 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Purine Derivatives as Ligands for A3 Adenosine Receptors
Current Topics in Medicinal Chemistry Hashimotos Thyroiditis: From Genes to the Disease
Current Genomics Preface:
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical Design Alternative Use of Bisphosphonate Therapy for Rheumatic Disease
Current Pharmaceutical Design MMP-2 Selectivity in Hydroxamate-Type Inhibitors
Current Medicinal Chemistry CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy
Current Gene Therapy Differential Pulse Voltammetric Determination of Piroxicam on Lanthanide Ferric Oxide Nanoparticles-Carbon Paste Modified Electrode
Current Pharmaceutical Analysis Optimizing Conventional Medical Therapies in Inflammatory Bowel Disease in 2014
Current Drug Targets Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design Other Potential Therapeutic Targets in Thyroid Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drugs, Trials and Pathogenesis: Will Connecting these Help us Understand SLE?
Current Rheumatology Reviews Antiangiogenesis Drug Design: Multiple Pathways Targeting Tumor Vasculature
Current Medicinal Chemistry Anti-Degenerative Effect of Melatonin on Intervertebral Disc: Protective Contribution against Inflammation, Oxidative Stress, Apoptosis, and Autophagy
Current Drug Targets Antiangiogenesis for Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery